To validate this prediction, patients and HD were stratified by therapy and we observed that high percentage of scMEP2 (in the case of HD and IFN-treated individuals) and scMEP9 (in rituximab/ocrelizumab group) were associated with breakthrough infection (Supplementary Fig. 27). This evidence concerns the gene IFNA1 and infection.